These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15736022)

  • 1. Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: what is the clinical significance?
    Connick E
    Clin Infect Dis; 2005 Mar; 40(6):874-5. PubMed ID: 15736022
    [No Abstract]   [Full Text] [Related]  

  • 2. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
    Hare CB; Pappalardo BL; Busch MP; Karlsson AC; Phelps BH; Alexander SS; Bentsen C; Ramstead CA; Nixon DF; Levy JA; Hecht FM
    Clin Infect Dis; 2006 Mar; 42(5):700-8. PubMed ID: 16447118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception?
    Eberle J; Notheis G; Blattmann C; Jung J; Buchholz B; Korn K; Kulozik AE; Schnitzler P
    AIDS; 2010 Nov; 24(17):2760-1. PubMed ID: 20980873
    [No Abstract]   [Full Text] [Related]  

  • 4. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy.
    Kassutto S; Johnston MN; Rosenberg ES
    Clin Infect Dis; 2005 Mar; 40(6):868-73. PubMed ID: 15736021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.
    Amor A; Toro C; Jiménez V; Simón A; Ramos B; Soriano V
    AIDS; 2006 Jun; 20(10):1460-2. PubMed ID: 16791025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 tropism, disease progression, and clinical management.
    Burger H; Hoover D
    J Infect Dis; 2008 Oct; 198(8):1095-7. PubMed ID: 18783314
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agents. New evidence changes guidelines about when to start treatment.
    TreatmentUpdate; 2009 Jan; 21(1):2-4. PubMed ID: 19248282
    [No Abstract]   [Full Text] [Related]  

  • 9. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.
    Chin BS; Lee SH; Kim GJ; Kee MK; Suh SD; Kim SS
    J Clin Microbiol; 2007 May; 45(5):1659-62. PubMed ID: 17344360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Drug holidays.
    TreatmentUpdate; 2003; 15(5):3-4. PubMed ID: 17216856
    [No Abstract]   [Full Text] [Related]  

  • 11. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Some researchers call for early HIV therapy.
    TreatmentUpdate; 2007 Jan; 19(1):1-2. PubMed ID: 17390476
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary HIV-1 infection: to treat or not to treat?
    Blankson JN
    AIDS Read; 2005 May; 15(5):245-6, 249-51. PubMed ID: 15900634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Is FOTO a treatment interruption that works?
    TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV agents. Why are drug holidays dangerous?
    TreatmentUpdate; 2009 Jan; 21(1):6-7. PubMed ID: 19248285
    [No Abstract]   [Full Text] [Related]  

  • 17. Serious non-AIDS conditions: redefining the spectrum of HIV-related disease.
    Baker J; Henry K
    AIDS Clin Care; 2007 Sep; 19(9):73-4, 80. PubMed ID: 18398992
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA notifications. Pediatric HIV infection guidelines for use of ARTs are revised.
    AIDS Alert; 2008 Apr; 23(4):46-7. PubMed ID: 19255980
    [No Abstract]   [Full Text] [Related]  

  • 20. Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy.
    Rice PS; Cybulska B; Parry JV; Rowland-Jones S; Daniels RS
    AIDS; 1999 Apr; 13(6):729-31. PubMed ID: 10397570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.